Bernhard Schlevogt

859 total citations
21 papers, 482 citations indexed

About

Bernhard Schlevogt is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Bernhard Schlevogt has authored 21 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 11 papers in Epidemiology and 3 papers in Infectious Diseases. Recurrent topics in Bernhard Schlevogt's work include Hepatitis C virus research (13 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (5 papers). Bernhard Schlevogt is often cited by papers focused on Hepatitis C virus research (13 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (5 papers). Bernhard Schlevogt collaborates with scholars based in Germany, Italy and Austria. Bernhard Schlevogt's co-authors include Ingo Bechmann, Michael Quinn, Markus P. Kummer, Katrin Kierdorf, Alexander Mildner, Michael T. Heneka, Daniel Erny, Marco Prinz, Josef Priller and Wolfgang Brück and has published in prestigious journals such as Journal of Neuroscience, Hepatology and Scientific Reports.

In The Last Decade

Bernhard Schlevogt

20 papers receiving 474 citations

Peers

Countries citing papers authored by Bernhard Schlevogt

Since Specialization

Citations

This map shows the geographic impact of Bernhard Schlevogt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard Schlevogt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard Schlevogt more than expected).

Fields of papers citing papers by Bernhard Schlevogt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard Schlevogt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard Schlevogt. The network helps show where Bernhard Schlevogt may publish in the future.

Co-authorship network of co-authors of Bernhard Schlevogt

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard Schlevogt. A scholar is included among the top collaborators of Bernhard Schlevogt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard Schlevogt. Bernhard Schlevogt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative analysis of SEC61A1 mutant R236C in two patient-derived cellular platforms 2024 ·Scientific Reports ·(unknown), (unknown), (unknown), Robert Schierwagen, Jonel Trebicka, Bernhard Schlevogt, Iyad Kabar, Hartmut Schmidt, Andree Zibert	0
2	Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series 2024 ·Hepatology ·(unknown), Elisabetta Degasperi, Mathias Jachs, Benjamin Maasoumy, Florian P. Reiter, Andreas Geier, (unknown), Christoph P. Berg, Kathrin Sprinzl, Stefan Zeuzem, (unknown), Bernhard Schlevogt, (unknown), Johannes Wiegand, R. Soffredini, Heiner Wedemeyer, Katja Deterding, Thomas Reiberger, Pietro Lampertico	14
3	Liver Injury after Selective Androgen Receptor Modulator Intake: A Case Report and Review of the Literature 2023 ·Zeitschrift für Gastroenterologie ·(unknown), Martin Bommer, (unknown), Gert Gabriëls, Hermann Pavenstädt, Inga Grünewald, Judit Horváth, Jonel Trebicka, Hartmut Schmidt, Bernhard Schlevogt	2
4	A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape 2023 ·Viruses ·(unknown), Heiko Slanina, M Roderfeld, Elke Roeb, Jonel Trebicka, John Ziebuhr, Wolfram H. Gerlich, Christian G. Schüttler, Bernhard Schlevogt, Dieter Glebe	1
5	Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing 2023 ·Emerging Microbes & Infections ·(unknown), Iyad Kabar, Hauke Heinzow, Benjamin Maasoumy, Birgit Bremer, Heiner Wedemeyer, Hartmut Schmidt, Thomas Pietschmann, Bernhard Schlevogt, Patrick Behrendt	5
6	Management of Hepatic Sarcoidosis 2022 ·Journal of Gastrointestinal and Liver Diseases ·(unknown), Bernhard Schlevogt, Hartmut Schmidt, (unknown), Peter R. Galle, (unknown), Christoph Antoni, Cleo‐Aron Weis, (unknown), Raoul Bergner, Matthias Ebert, Andreas Teufel	7
7	A SEC61A1 variant is associated with autosomal dominant polycystic liver disease 2022 ·Liver International ·Bernhard Schlevogt, (unknown), (unknown), Rita Schröter, Thomas E. Wagner, (unknown), Andree Zibert, Hartmut Schmidt, Carsten Bergmann, Pavel I. Nedvetsky, Michael P. Krahn	5
8	Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis 2020 ·Hepatology ·(unknown), Hartmut Schmidt, Bernhard Schlevogt	5
9	Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment 2019 ·Pathogens ·Bernhard Schlevogt, Volker Kinast, Julia Reusch, Andrea Kerkhoff, Dimas Praditya, Daniel Tödt, Hartmut Schmidt, Eike Steinmann, Patrick Behrendt	7
10	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection 2018 ·Liver Cancer ·(unknown), Bernhard Schlevogt, (unknown), Mohammad Kabbani, Katja Deterding, Thomas Wirth, Arndt Vogel, Michael P. Manns, Christine S. Falk, Markus Cornberg, Heiner Wedemeyer	28
11	Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis 2017 ·Alimentary Pharmacology & Therapeutics ·(unknown), Bernhard Schlevogt, Katja Deterding, Anika Wranke, (unknown), Kerstin Port, M P Manns, Arndt Vogel, Markus Cornberg, Heiner Wedemeyer	54
12	Hepatobiliary and Pancreatic: Fulminant liver failure from diffuse leukemoid hepatic infiltration of melanoma 2017 ·Journal of Gastroenterology and Hepatology ·Bernhard Schlevogt, (unknown), Benedikt Hild, (unknown)	4
13	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras 2017 ·Journal of Hepatology ·S. Süsser, Julia Dietz, Bernhard Schlevogt, Eli Zuckerman, Manouchehr Barak, Valeria Piazzolla, A Howe, Holger Hinrichsen, (unknown), (unknown), Markus Cornberg, Alessandra Mangia, Stefan Zeuzem, Christoph Sarrazin	20
14	Interferon-free cure of hepatitis C virus infection does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis 2017 ·Journal of Hepatology ·(unknown), Christine S. Falk, (unknown), Bernhard Schlevogt, Katja Deterding, M.P. Manns, Andrea Vogel, (unknown), Markus Cornberg, H. Wedemeyer	2
15	Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis 2017 ·Journal of Hepatology ·(unknown), Bernhard Schlevogt, Katja Deterding, Anika Wranke, Kerstin Port, M.P. Manns, Andrea Vogel, Markus Cornberg, H. Wedemeyer	2
16	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up 2017 ·Zeitschrift für Gastroenterologie ·Bernhard Schlevogt, Katja Deterding, Kerstin Port, Christoph Höner zu Siederdissen, (unknown), J. Kirschner, Carola Mix, Michael Manns, Markus Cornberg, Heiner Wedemeyer	17
17	Real‐world effect of ribavirin on quality of life in HCV‐infected patients receiving interferon‐free treatment 2017 ·Liver International ·Christoph Höner zu Siederdissen, Bernhard Schlevogt, Philipp Solbach, Kerstin Port, Markus Cornberg, Michael P. Manns, Heiner Wedemeyer, Katja Deterding	9
18	Weight Gain after IFN-Free Cure of Chronic Hepatitis C: A Potential Concern? 2016 ·Journal of Hepatology ·Bernhard Schlevogt, Katja Deterding, Kerstin Port, J. Kirschner, (unknown), Carola Mix, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer	4
19	Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras 2016 ·Journal of Hepatology ·S. Süsser, Julia Dietz, Manouchehr Barak, Bernhard Schlevogt, (unknown), Valeria Piazzolla, (unknown), Markus Cornberg, E. Zuckerman, Alessandra Mangia, Stefan Zeuzem, C. Sarrazin	8
20	Distinct and Non-Redundant Roles of Microglia and Myeloid Subsets in Mouse Models of Alzheimer's Disease 2011 ·Journal of Neuroscience ·Alexander Mildner, Bernhard Schlevogt, Katrin Kierdorf, Chotima Böttcher, Daniel Erny, Markus P. Kummer, Michael Quinn, Wolfgang Brück, Ingo Bechmann, Michael T. Heneka, Josef Priller, Marco Prinz	277

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact